Suppr超能文献

具有致病变异的异时性双侧乳腺癌中癌症基因组图谱的动态变化

Dynamic change of cancer genome profiling in metachronous bilateral breast cancer with pathogenic variant.

作者信息

Kimura Ayako, Nakagomi Hiroshi, Inoue Masayuki, Oka Tomomi, Hirotsu Yosuke, Amemiya Kenji, Mochizuki Hitoshi, Oyama Toshio, Omata Masao

机构信息

Department of Breast Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi 400-8506 Japan.

Genome Analysis Center, Yamanashi Prefectural Central Hospital, Kofu, Japan.

出版信息

Int Cancer Conf J. 2024 May 11;13(3):193-198. doi: 10.1007/s13691-024-00685-3. eCollection 2024 Jul.

Abstract

A 61-year-old woman with pathogenic variant had been treated for 20 years and showed dynamic changes in the genomic profile of her metachronous bilateral breast cancer and metastases. She underwent right breast conservation surgery at age 42-Genome 1, lung metastasis and left axillary lymph node metastasis at age 51, partial excision under local anesthesia for left breast cancer at age 53-Genome 2, left axillary lymph node dissection was added 6 month later-Genome 3. Then, olaparib was administered, and subsequently, left mastectomy was performed for the recurrence of left breast cancer at age 59-Genome 4. Genomic profile of the tumor was analyzed at four points (Genome 1-3 were analyzed by in house breast cancer panel, and Genome 4 was analyzed by Foundation One CDx). Two interesting findings emerged from these analyses. First, the genomic profile revealed that the left axillary lymph node metastasis, considered histologically from right breast cancer, was a metastasis from the left breast cancer. The second finding is that as the disease progressed, mutation profile became more diverse. The profile of the left breast cancer removed after olaparib and other treatments showed reversion mutation of and was diagnosed as tumor mutation burden high. Subsequent response to pembrolizumab was favorable.

摘要

一名携带致病变异的61岁女性已接受治疗20年,其异时性双侧乳腺癌及转移灶的基因组图谱呈现动态变化。她42岁时接受了右乳保乳手术——基因组1,51岁时出现肺转移和左腋窝淋巴结转移,53岁时因左乳腺癌在局部麻醉下进行了部分切除——基因组2,6个月后增加了左腋窝淋巴结清扫术——基因组3。然后,给予奥拉帕利治疗,随后,59岁时因左乳腺癌复发进行了左乳房切除术——基因组4。在四个时间点对肿瘤的基因组图谱进行了分析(基因组1 - 3通过内部乳腺癌检测板进行分析,基因组4通过Foundation One CDx进行分析)。这些分析得出了两个有趣的发现。首先,基因组图谱显示,从组织学上看被认为是右乳腺癌转移的左腋窝淋巴结转移,实际上是左乳腺癌的转移。第二个发现是,随着疾病进展,突变谱变得更加多样化。在接受奥拉帕利和其他治疗后切除的左乳腺癌的图谱显示了 的回复突变,并被诊断为肿瘤突变负荷高。随后对帕博利珠单抗的反应良好。

相似文献

1
Dynamic change of cancer genome profiling in metachronous bilateral breast cancer with pathogenic variant.
Int Cancer Conf J. 2024 May 11;13(3):193-198. doi: 10.1007/s13691-024-00685-3. eCollection 2024 Jul.
2
Germline BRCA2 Pathogenic Variant in Primary Breast Cancer of a Down Syndrome Individual.
Am J Case Rep. 2023 Dec 29;24:e942208. doi: 10.12659/AJCR.942208.
5
A Case of -Pathogenic Variant Breast Cancer With Metachronous Endometrial Cancer and Pancreatic Cancer.
World J Oncol. 2023 Aug;14(4):309-315. doi: 10.14740/wjon1658. Epub 2023 Aug 4.
7
A case of hereditary metachronous bilateral triple-negative breast cancer that was highly sensitive to carboplatin.
J Surg Case Rep. 2021 Apr 14;2021(4):rjab018. doi: 10.1093/jscr/rjab018. eCollection 2021 Apr.
8
Contralateral axillary lymph node metastasis in primary breast cancer: A case report.
Int J Surg Case Rep. 2022 Mar;92:106810. doi: 10.1016/j.ijscr.2022.106810. Epub 2022 Feb 4.

本文引用的文献

1
Comprehensive genomic profiling: Does timing matter?
Front Oncol. 2023 Feb 14;13:1025367. doi: 10.3389/fonc.2023.1025367. eCollection 2023.
2
Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice.
Cancer Sci. 2022 Dec;113(12):4300-4310. doi: 10.1111/cas.15586. Epub 2022 Sep 29.
3
-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms.
Cancers (Basel). 2022 May 16;14(10):2453. doi: 10.3390/cancers14102453.
4
PIK3CA-AKT pathway predominantly acts in developing ipsilateral breast tumor recurrence long after breast-conserving surgery.
Breast Cancer Res Treat. 2022 Jun;193(2):349-359. doi: 10.1007/s10549-022-06570-y. Epub 2022 Mar 25.
5
Association of BRCA Mutations and Pancreatic Cancer: Review of Literature and Meta-analysis.
Pancreas. 2022 Jan 1;51(1):e8-e10. doi: 10.1097/MPA.0000000000001956.
6
Tackling PARP inhibitor resistance.
Trends Cancer. 2021 Dec;7(12):1102-1118. doi: 10.1016/j.trecan.2021.08.007. Epub 2021 Sep 22.
8
Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice.
Cancers (Basel). 2020 May 4;12(5):1156. doi: 10.3390/cancers12051156.
10
Prevalence and mutational determinants of high tumor mutation burden in breast cancer.
Ann Oncol. 2020 Mar;31(3):387-394. doi: 10.1016/j.annonc.2019.11.010. Epub 2020 Jan 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验